GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Issuance of Debt

Apollon Formularies (AQSE:APOL) Issuance of Debt : £0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Issuance of Debt?

Apollon Formularies's Issuance of Debt for the six months ended in Jun. 2023 was £0.00 Mil.

Apollon Formularies's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00 Mil.


Apollon Formularies Issuance of Debt Historical Data

The historical data trend for Apollon Formularies's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Issuance of Debt Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.07 -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Apollon Formularies Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Jeff Auxier Interview with GuruFocus

By Holly LaFon Holly LaFon 08-28-2012

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013